# EDGAR Filing Document

**Accession Number:** 0001345099
**File Stem:** 0001345099-26-000039
**Filing Date:** 2026-4
**Character Count:** 3677
**Document Hash:** 154d6c0e4ea8c8399edf6cd5b27b8c03
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001345099-26-000039.hdr.sgml**: 20260408

**ACCESSION NUMBER**: 0001345099-26-000039

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260408

**FILED AS OF DATE**: 20260408

**DATE AS OF CHANGE**: 20260408

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MESOBLAST LTD
- **CENTRAL INDEX KEY:** 0001345099
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C3
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37626
- **FILM NUMBER:** 26846437

**BUSINESS ADDRESS:**
- **STREET 1:** LEVEL 38
- **STREET 2:** 55 COLLINS STREET
- **CITY:** MELBOURNE, VICTORIA
- **STATE:** C3
- **ZIP:** 3000
- **BUSINESS PHONE:** 613 9639 6036

**MAIL ADDRESS:**
- **STREET 1:** LEVEL 38
- **STREET 2:** 55 COLLINS STREET
- **CITY:** MELBOURNE, VICTORIA
- **STATE:** C3
- **ZIP:** 3000

**UNITED STATES <br>SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K** 

**Report of Foreign Private Issuer<br>Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934** 

**For the month of April 2026**

**Commission File Number 001-37626**

**Mesoblast Limited** 

(*Exact name of Registrant as specified in its charter*)

**Not Applicable**

(*Translation of Registrant's name into English)*

**Australia**<br>(*Jurisdiction of incorporation or organization)*

**Silviu Itescu**

**Chief Executive Officer and Executive Director**

**Level 38**

**55 Collins Street**

**Melbourne 3000**

**Australia** 

(*Address of principal executive offices*)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

Form 20-F ☑ Form 40-F ☐

------

**INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K**

On April 7, 2026, Mesoblast Limited filed with the Australian Securities Exchange a new issue announcement, proposed issue of securities (Appendix 3B) which is attached hereto as <u>Exhibit 99.1</u>, and is incorporated herein by reference.

On April 8, 2026, Mesoblast Limited filed with the Australian Securities Exchange a new issue announcement, application for quotation of securities (Appendix 2A) which is attached hereto as <u>Exhibit 99.2</u>, and is incorporated herein by reference.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.

---

| |
|:---|
| <br>Mesoblast Limited |
| /s/ Niva Sivakumar |
| Niva Sivakumar |
| *Company Secretary* |

---

Dated: April 8, 2026

------

**INDEX TO EXHIBITS**

---

| | |
|:---|:---|
| Item | |
| <u>[99.1](exhibit991chymalappendix.htm)</u> | Appendix 3B of Mesoblast Ltd, dated April 7, 2026 |
| <u>[99.2](exhibit992chymalappendix.htm)</u> | Appendix 2A of Mesoblast Ltd, dated April 8, 2026 |

---

## Exhibit 99.1

![](exhibit991chymalappendix001.jpg)

Exhibit 99.1

------

![](exhibit991chymalappendix002.jpg)

------

![](exhibit991chymalappendix003.jpg)

------

![](exhibit991chymalappendix004.jpg)

------

![](exhibit991chymalappendix005.jpg)

------

## Exhibit 99.2

![](exhibit992chymalappendix001.jpg)

Exhibit 99.2

------

![](exhibit992chymalappendix002.jpg)

------

![](exhibit992chymalappendix003.jpg)

------

![](exhibit992chymalappendix004.jpg)

------

![](exhibit992chymalappendix005.jpg)

------

![](exhibit992chymalappendix006.jpg)

------